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Abstract
Transglutaminase 2 (TG2) is an allosterically regulated enzyme with transamidating, deamidating and cell signaling
activities. It is thought to catalyze sequence-specific deamidation of dietary gluten peptides in the small intestines of celiac
disease patients. Because this modification has profound consequences for disease pathogenesis, there is considerable
interest in the design of small molecule TG2 inhibitors. Although many classes of TG2 inhibitors have been reported, thus far
an animal model for screening them to identify promising celiac drug candidates has remained elusive. Using
intraperitoneal administration of the toll-like receptor 3 (TLR3) ligand, polyinosinic-polycytidylic acid (poly(I:C)), we induced
rapid TG2 activation in the mouse small intestine. Dose dependence was observed in the activation of TG2 as well as the
associated villous atrophy, gross clinical response, and rise in serum concentration of the IL-15/IL-15R complex. TG2 activity
was most pronounced in the upper small intestine. No evidence of TG2 activation was observed in the lung mucosa, nor
were TLR7/8 ligands able to elicit an analogous response. Introduction of ERW1041E, a small molecule TG2 inhibitor, in this
mouse model resulted in TG2 inhibition in the small intestine. TG2 inhibition had no effect on villous atrophy, suggesting
that activation of this enzyme is a consequence, rather than a cause, of poly(I:C) induced enteropathy. Consistent with this
finding, administration of poly(I:C) to TG2 knockout mice also induced villous atrophy. Our findings pave the way for
pharmacological evaluation of small molecule TG2 inhibitors as drug candidates for celiac disease.
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Introduction
Transglutaminase 2 (TG2, a.k.a. tissue transglutaminase) is a
ubiquitous multifunctional mammalian protein that catalyzes the
formation of intermolecular isopeptide bonds between glutamine
and lysine residues of selected proteins [1–3]. Its enzymatic activity
is allosterically regulated by several factors, including guanine
nucleotides, Ca
+2, and redox potential [4–6]. In pathological
situations, such as in the small intestinal mucosa of celiac disease
patients, TG2 can also deamidate glutamine residues of gluten
peptides, creating potent T cell epitopes [7–9]. Therefore, TG2
inhibitors are thought to represent promising avenues for celiac
disease therapy [9].
Although numerous small molecule TG2 inhibitors have been
reported to date [10–16], an assay to compare their relative
efficacy in vivo has remained elusive. The target organ for celiac
disease therapy is the upper small intestine; however, TG2 is in a
catalytically inactive state in the intestinal mucosa of healthy
rodents [17]. Therefore, a prerequisite for assessing inhibitor
pharmacodynamics is the development of a model system in which
TG2 is activated in the upper small intestine in response to an
inflammatory trigger. Recently, we reported that intraperitoneal
injection of polyinosinic-polysytidylic acid (poly(I:C)), a toll-like
receptor 3 (TLR3) ligand, led to rapid activation of TG2 in the
small intestinal mucosa of C57BL/6J mice [17]. Poly(I:C) is a
synthetic analog of double-stranded RNA that has been widely
used to mimic viral infection. Our protocol, which was based on
earlier reports demonstrating an enteropathic response to poly(I:C)
in mice [18,19], set the stage for developing a pharmacological
assay to measure the potency of small molecule TG2 inhibitors in
the upper intestine. Here we characterize this assay in greater
detail, and exploit it to identify a bona fide lead compound,
ERW1041E, for celiac drug discovery.
Results
Dose dependence of the poly(I:C) mediated
inflammatory response
Earlier studies have shown that intraperitoneal injection of a
single 30 mg/kg dose of poly(I:C) in C57BL/6J mice induced
severe small intestinal injury that is characterized by villous
atrophy, an increase in serum concentrations of IL-15, and
activation of TG2 [17,18]. Activation of TG2, as measured by
incorporation of the TG2 substrate 5-biotinylamide pentylamine
(5BP), occurred within a few hours after poly(I:C) administration,
and was most pronounced at the villus tips. To explore the dose
dependence of this acute inflammatory condition, we first sought
to standardize the procedure for preparing poly(I:C), because
preliminary studies revealed that commercial poly(I:C) was
unsuitable for quantitative experimentation (data not shown).
Poly(I:C) was dissolved in sterile PBS at room temperature.
The solution was heated to 85uC for 3 min, and subsequently
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room temperature. We have found that poly(I:C) prepared by this
procedure results in reproducible intestinal injury as compared to
using it directly as purchased from the vendor. The final poly(I:C)
concentration was measured at 260 nm, and used to inject mice
at 30, 20, 15, or 5 mg/kg. The duodenal mucosa of most mice
exposed to the three highest doses revealed TG2 activation,
especially at villus tips, with a clear dose-dependent pattern
(Figure 1). Corresponding levels of villous atrophy were
confirmed by H&E staining (Figure 2). Low levels of TG2
activity could also be detected in some mice injected with 5 mg/
kg poly(I:C) (Figure 1). Importantly, mice treated with 30 mg/kg
showed severe acute symptoms and intestinal lesions, whereas
lower poly(I:C) doses did not elicit comparable effects. Intestinal
sections collected from control cohorts treated with 0 mg/kg
poly(I:C) followed by 5BP showed normal histology with no TG2
activity (data not shown). The serum concentrations of the IL-15/
IL-15R complex correlated well with histological and clinical
severity of the animals (Figure 3). Both intestinal inflammation
and TG2 activity were transient phenomena as mice treated with
sub-lethal doses of poly(I:C) recovered in 24–48 h (data not
shown).
Figure 1. Treatment of C57BL/6J mice with poly(I:C) results in villous atrophy and activation of TG2 at the villus tips. Single
intraperitoneal injections of 30 (a–d), 20 (e–h), 15 (i–l), 5 (m–p), or 0 (q–t) mg/kg poly(I:C) were administered. Mice were sacrificed after 9 h, and small
intestines collected and frozen in OCT. Sections of 20 mm thickness were cut, fixed, washed, permeabilized, and exposed first to a rabbit anti-TG2
antibody (ab421) followed by a secondary Alexa fluor 488-congugated goat anti-rabbit IgG (c, g, k, o, s). Total TG2 protein (active and non active) is
shown. TG2 activity after poly(I:C) injury, measured using 5BP crosslinking, was visualized by co-staining with Alexa fluor 555-conjugated streptavidin
(b, f, j, n, r). Nuclei were stained with DAPI (a, e, i, m, q). Overlays of the three stains are shown in (d, h, l, p, t). At least 3 animals were tested at each
poly(I:C) dose shown; one representative duodenal section is shown.
doi:10.1371/journal.pone.0030642.g001
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mediated TG2 activation, mucosa along the length of the intestine
as well as the lungs were examined. As shown in Figure 4, TG2
activity was most pronounced in the duodenum, and decreased
progressively in the jejunum and ileum. No evidence of 5BP
crosslinking was observed in lung mucosa (data not shown). To
determine whether other TLR ligands could induce TG2 activity
in the small intestine, C57BL/6J mice were injected with R848, a
potent TLR7/8 agonist [20]. Again, no changes were observed in
either the gross histological architecture or the TG2 activity in the
duodenum (data not shown).
Inhibition of catalytically active TG2 in the small intestine
by small molecule inhibitors
Having characterized the dose-response of the mouse small
intestine to poly(I:C), we sought to determine whether transiently
activated TG2 could be pharmacologically inhibited. To simulate
sub-lethal inflammatory conditions, poly(I:C) doses of 15 and
20 mg/kg were selected for these experiments. Over the course of
these studies, we screened several TG2 inhibitors for efficacy and
tolerability. One compound in particular, ERW1041E, was well
tolerated in chronic administration regimens up to 50 mg/kg
(Figure 5), and was also able to inhibit small intestinal TG2 activity
in poly(I:C) treated mice in a dose-dependent manner (data not
shown). TG2 inhibition had no effect on the observed villous
atrophy (data not shown), suggesting that activation of this enzyme
is a consequence, rather than a cause, of poly(I:C) induced
enteropathy.
Effect of poly(I:C) in TG2 knockout mice
To confirm that the elevated 5BP incorporation at duodenal
villus tips was indeed due to TG2 activity, we examined the effect
of poly(I:C) in TG2-knockout mice [21]. Intraperitoneal injection
of a single 20 mg/kg dose of poly(I:C) induced small intestinal
injury and villous atrophy (Figure 6), verifying that the
inflammatory effects of poly(I:C) did not depend upon TG2
activity. Indeed, the toxicity of poly(I:C) appeared to be
considerably more severe in TG2-knockout mice than in wild-
type mice, as judged by the high lethality at the 20 mg/kg dose in
the former strain (significant lethality (2/7) was observed in
poly(I:C)-treated mice). An intense distribution of 5BP was
observed in duodenal cross-sections of TG2-knockout mice treated
with poly(I:C) (Figure 6f). However, in contrast to wild-type
animals (e.g. see Figures 1f or 5j), the 5BP was uniformly
distributed throughout the mucosa, and was not concentrated at
the tips of blunted villi. Moreover, co-treatment of TG2-knockout
mice with poly(I:C) and the TG2 inhibitor ERW1041E showed no
difference in the intensity or distribution of 5BP incorporation
(Figure 6, panel f versus j). Together, these results demonstrate that
TG2 is rapidly activated in duodenal villus tips of wild-type (but
not TG2-knockout) mice, and that transient TG2 activity can be
inhibited by small molecule inhibitors of this enzyme.
Discussion
The search for TG2 inhibitors that are appropriate drug
candidates for celiac disease therapy requires a number of
successive pharmacological assays of increasing complexity and
information content. Naturally, the primary screen is a kinetic
assay for enzyme inhibition. Quantitative biochemical assays for
TG2 activity are well established [22,23], and can be implemented
in a variety of moderately high-throughput formats for screening
small molecules to identify TG2 inhibitors. As a next step, a cell-
based assay is desirable to assess the tolerability and activity of
promising inhibitors in biological systems. Because both intracel-
lular and extracellular TG2 pools associated with typical cultured
cell lines are catalytically inactive, we previously developed a
fibroblast scratch assay for this purpose [17,24]. TG2 is rapidly
activated when WI-38 fibroblast cells grown on fibronectin-coated
surfaces are gently scratched with a pipet tip, a phenomenon that
mimics the well-documented role of TG2 in wound healing [17].
Activated TG2 can be either directly visualized with ‘‘clickable’’
active site-directed probes [24], or indirectly using the biotinylated
Figure 2. H&E staining of duodenal cross sections from mice treated with poly(I:C) at 30 mg/kg (A), 15 mg/kg (B), or 0 mg/kg
poly(I:C) (C). Animals were sacrificed 9 h after poly(I:C) administration, and their small intestines were harvested.
doi:10.1371/journal.pone.0030642.g002
Figure 3. Serum levels of IL-15R/IL-15 in response to poly(I:C).
Treatment with poly(I:C) increased the levels of IL-15R/IL-15 in serum.
All of the mice in this experiment except those receiving no poly(I:C)
and one of the mice injected with 15 mg/kg poly(I:C) (the one with low
levels of IL15Ra/IL-15), developed enteropathy. Given values are mean
of duplicate measurements for each mouse (error bars indicate SD for
each measurement). The overall experiment was repeated twice with
similar results.
doi:10.1371/journal.pone.0030642.g003
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TG2 substrates [2]. For example, the minimum inhibitory
concentration (MIC) of the dihydroisoxazole TG2 inhibitor,
ERW1041E (1, [15,24]) is 6.25–12.5 mM in this assay. In this
study, we elicit small intestinal injury in C57BL/6J mice using
poly(I:C), and test the ability of ERW1041E to inhibit transiently
activated TG2 in intestinal mucosa. To our knowledge, the
current report is the first description of an in vivo assay for TG2
inhibition in the mammalian intestine.
Toll-like receptors (TLR) are innate immune system sensors that
detect pathogen-associated molecules such as bacterial lipopoly-
saccharides and viral double-stranded RNA, and trigger a broader
immune response. Poly(I:C) is a TLR3 ligand that mimics viral
infection. Treatment of mice with this pro-inflammatory agent
induces villous atrophy in the small intestine, and also results in the
activation of mucosal TG2. This response is localized to the small
intestine, in particular to the duodenum and jejunum, and does
not appear to be achievable by alternative TLR receptors. Thus,
future efforts to develop non-dietary celiac therapies that block
TG2 should be tested in this in vivo assay with ERW1041E as a
reference compound.
Notwithstanding the pharmacological promise of this animal
model, the assay has certain fundamental and practical
limitations. First, the mechanism of inducing TG2 activity in
the small intestine does not involve gluten, and is therefore not
directly relevant to celiac disease pathogenesis. Although
encouraging progress has been made recently towards the
development of a mouse model for celiac disease [25], much
remains to be learned about the mechanism by which gluten
peptides induce TG2 activation in the celiac intestinal mucosa. It
is likely that improved models for intestinal TG2 activation and
inhibitor evaluation will emerge, as more insight emerges into this
phenomenon of critical importance to celiac disease pathogenesis.
Second, whereas a fundamental premise of TG2 blockers as
celiac drug candidates is that inhibition of this target can prevent
intestinal inflammation in a patient, our results clearly demon-
strate that TG2 activity is not a requisite for poly(I:C) mediated
intestinal inflammation. Thus, even though our animal model can
facilitate quantitative discrimination between alternative drug
candidates, it does not test the core hypothesis underlying this
mode of action of a celiac drug candidate. In this regard it may
be worth assessing intestinal TG2 activity in a model where low
doses of poly(I:C) are used as an adjuvant to induce a T cell
response to an antigen [26], preferably a gluten antigen [27]. If
the coordinated response of the innate and adaptive immune
systems in such a model result in higher intestinal TG2 activity
than can be achieved by either mechanism alone, then TG2
inhibition in such a model may result in biological consequences
of relevance to celiac disease. Last but not least, the stepwise
injection of three separate reagents (poly(I:C), TG2 inhibitor, and
5BP) in our current mouse model is cumbersome, and could be
improved. Usage of TG2 inhibitors that can be administered via
oral gavage would not only simplify the protocol, but would also
enable the evaluation of oral bioavailability of improved celiac
drug candidates. At the same time, the simultaneous administra-
tion of ‘‘clickable’’ probes of activated TG2 in the mouse intestine
would simplify both the in-life as well as post-sacrifice stages of
our experimental protocol.
Figure 4. Localization of TG2 activity in the small intestine of poly(I:C)-treated mice. Mice were treated with 30 mg/kg poly(I:C), and
samples were collected from the duodenum (a–d), jejunum (e–h), and ileum (i–l). Active TG2 was detected by exposing cross-sections to Alexa fluor
555-conjugated (b, f, j). The total amount of TG2 protein in these sections was visualized by co-staining with polyclonal anti-TG2 antibody, followed
by an Alexa fluor 488-conjugated secondary antibody (c, g, k). Nuclei were stained with DAPI (a, e, i). Overlays are shown in the right column (d, h, l).
Scale bar represents 300 mm and applies to all panels. At least 4 animals were tested; one representative section is shown for each intestinal segment.
doi:10.1371/journal.pone.0030642.g004
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PLoS ONE | www.plosone.org 4 February 2012 | Volume 7 | Issue 2 | e30642Figure 5. Inhibition of TG2 activity by ERW1041E in the small intestine of poly(I:C)-treated mice. Mice were treated with 20 mg/kg (i–p),
or 15 mg/kg (q–x) poly(I:C), followed by two intraperitoneal injections of vehicle (i–l; q–t) or 50 mg/kg ERW1041E (m–p; u-bb) at 6 h and 9 h. Control
cohorts were dosed with no pharmacological agent (a–d), only 5BP (e–h) or ERW1041E and 5BP (y-bb). TG2 activity was detected by exposing
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Antibodies
The antibodies used were anti-TG2 IgG produced in rabbit
(Abcam, ab421) and Alexa fluor 488-conjugated goat anti-rabbit
IgG (H-L) antibody (Invitrogen, A-11008). Alexa fluor 555-labeled
streptavidin (Invitrogen, S-21381) was used to detect 5BP.
Synthesis of TG2 inhibitors
Inhibitor 1 was synthesized as previously described [15].
Poly(I:C) preparation
Poly(I:C) (Sigma, P1530) was dissolved in PBS at room
temperature. The solution was heated to 85uC for 3 min, and
subsequently annealed by allowing it to cool by 1uC per min, until
it reached room temperature. The final poly(I:C) concentration
was measured at 260 nm, and used to inject mice at the desired
concentration.
Poly(I:C) induced small intestinal injury in mice
C57BL/6 mice or TG2-knockout mice (Nanda et al., 2001) (8
weeks old) were IP injected with 30 mg/kg poly(I:C) (Sigma,
P1530) dissolved in sterile PBS to injure the small intestine as
described previously [17]. Controls were given vehicle (PBS only).
5BP (Thermo scientific, 21345) was dissolved to 25 mg/ml in
sterile PBS. Mice were IP injected twice with either 100 mg/kg
5BP or PBS at three hr intervals. For mice sacrificed after 9 hrs,
5BP was injected at 6 and 9 hrs. Mice were sacrificed using CO2
inhalation at the end of the experiment and blood samples were
collected via cardiac puncture. The small intestines and lungs were
collected and formalin-fixed for H&E staining or embedded in
OCT and flash-frozen in liquid N2 for subsequent cryosectioning
and immunohistochemistry.
TG2 inhibition in mice
Compound 1 was purified by HPLC, and dissolved in 20%
DMSO in sterile PBS at 4 mg/ml for intraperitoneal injections.
duodenal cross-sections to Alexa fluor 555-conjugated streptavidin (b, f, j, n, r, v, z). TG2 protein was visualized by co-staining with polyclonal anti-TG2
antibody, followed by a secondary antibody conjugated to Alexa fluor 488 (c, g, k, o, s, w, aa). Nuclei were visualized by staining with DAPI (a, e, i, m,
q, u, y). The right column contains overlay images (d, h, l, p, t, x, bb). At least 3 animals were tested in each cohort; one representative duodenal
section is shown.
doi:10.1371/journal.pone.0030642.g005
Figure 6. Effects of poly(I:C) treatment on TG2 knockout mice. Mice were treated with 0 mg/kg (a–d) or 20 mg/kg (e–l) poly(I:C), followed by
two intraperitoneal injections of PBS (a–d), or 100 mg/kg (e–l) 5BP at 6 h and 9 h. Poly(I:C)-treated mice were subsequently administered 50 mg/kg
ERW1041E. TG2 activity was detected by exposing duodenal cross-sections to Alexa fluor 555-conjugated streptavidin (b, f, j). TG2 protein was
visualized by co-staining with polyclonal anti-TG2 antibody, followed by a secondary antibody conjugated with Alexa fluor 488 (c, g, k). Nuclei were
stained with DAPI (a, e, i). Overlays are shown in the right column (d, h, l). At least 3 animals were tested in each cohort; one representative duodenal
section is shown. Unlike wild-type mice, significant lethality (2/7) was observed in poly(I:C)-treated mice. The structure of ERW1041E (1) is shown.
doi:10.1371/journal.pone.0030642.g006
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peritoneally (IP) at 15 or 50 mg/kg.
H&E staining
For histology, tissue from the small intestine was fixed in
formalin and embedded in paraffin. Four-micrometer sections
were affixed to slides, deparaffinized, and stained with hematox-
ylin and eosin (H&E) stain. Morphological changes in the stained
sections were examined under light microscopy. Brightfield images
were taken using a Zeiss Axiophot upright microscope with
Axiovision software (version 4.2).
Immunohistochemistry on frozen sections
Twenty mm cryosections were cut from OCT embedded tissues.
Sections were fixed with 4% paraformaldehyde (PFA) for 10 min
at RT. Sections were washed three times with PBS/0.1% Tween
20 (PBT) for 5 mins. Sections were then permeabilized with PBS/
0.3% Triton X-100 for 10 min at RT, washed extensively with
PBT two times for 5 mins, then blocked in 0.3% Triton X-100
and 5% goat serum in PBS (preblock buffer) in humid chamber as
300 ml per slide from 30 min – 4 hr at RT then probed with rabbit
anti-transglutaminase 2 antibody (ab421) diluted in preblock
buffer (1:250) over night at 4uC. Slides were rinsed in PBS-Tween
20 (0.1% Tween-20) three times for 5 mins each then incubated
with the Alexa-488 conjugated goat anti rabbit IgG (H+L) (A-
11034, Invitrogen) (1:250) and streptavidin-Alexa 555 diluted in
preblock buffer (1:250) for 45 mins at RT. Then, slides were
washed three times in PBT for 5 mins each and stained with DAPI
in PBT at RT for 5 mins and finally washed twice with PBT for
5 mins. Slides were mounted with 150 ml Mowiol 4–88 (Calbio-
chem) with 2.5% DABCO anti-photobleaching reagent (Sigma).
Images were obtained on a Leica Sp2 confocal microscope, using
LCS software.
ELISA
Serum samples were kept frozen at 280uC until ready for
cytokine measurement. The level of IL15R/IL-15 was measured
using the mouse IL-15R/IL-15 complex ELISA Ready-SET-Go
kit (eBioscience, 88-7215-22) from eBiosciences, following the
manufacturer’s protocol using serum at a 1:20 dilution.
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